Posts tagged top-line data
WB drops coverage of OncoGenex

William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday.

“We note that AFFINITY is the key study of the lead asset, custirsen, as a chemotherapy companion in the second-line chemo setting in metastatic castration resistant prostate cancer,” writes analyst Katherine Xu. 

Read More
Dipexium completes enrollment in second Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollmentin the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide.

Last week, the company reached the enrollment objective in the OneStep-2 pivotal trial.

Read More
Rodman starts Presbia at buy

Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday.

Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness.

Read More